NCT05504057View on ClinicalTrials.gov

Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection

RecruitingOBSERVATIONAL
Enrollment

140,660

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

January 19, 2025

Study Completion Date

February 24, 2028

Conditions
COVID-19
Interventions
DRUG

Antihistamine

Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines

DRUG

Amantadine

Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine

Trial Locations (2)

08227

RECRUITING

Hospital de Terrassa, Terrassa

RECRUITING

Hospital of Terrassa, Terrassa

All Listed Sponsors
collaborator

Institut Català de la Salut

OTHER

lead

Consorci Sanitari de Terrassa

OTHER